{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:13Z","timestamp":1793575033581,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the efficacy of biologics in preventing radiographic progression in peripheral joints of PsA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Studies were searched in MEDLINE, Web of Science, and abstracts from the last three EULAR and ACR meetings up to 31 December 2019. Primary and secondary endpoints were the proportion of patients without radiographic progression and the mean change in total radiographic score at week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eleven studies, involving 5382 patients, 9 drugs and 18 treatments, were included. Patients receiving biologics were more likely to achieve radiographic non-progression compared with placebo [odds ratio: pooled: 2.40, 95% CI: 2.00, 2.87; TNF inhibitors (TNFi): 2.94, 95% CI: 2.38, 3.63; IL inhibitors (ILi): 2.15, 95% CI: 1.69, 2.74; abatacept: 1.54, 95% CI: 1.03, 2.28] and have significantly lower radiographic progression [standardized mean difference (SMD): pooled: \u22122.16, 95% CI: \u22122.91, \u22121.41; TNFi: \u22122.82, 95% CI: \u22124.31, \u22121.33; ILi: \u22121.60, 95% CI: \u22122.49, \u22120.72; abatacept: \u22120.40, 95% CI: \u22120.59, \u22120.21]. Concomitant MTX therapy was not superior to monotherapy (SMD: pooled: 0.01, 95% CI: \u22120.07, 0.08; biologics: 0.01, 95% CI: \u22120.09, 0.11; placebo: \u22120.01, 95% CI: \u22120.13, 0.12). The effect of ustekinumab and secukinumab on radiographic progression was not influenced by prior anti-TNF therapy (SMD: \u22120.08, 95% CI: \u22120.25, 0.10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Biologic agents may retard radiographic progression in PsA patients in terms of bone erosion and joint space narrowing compared with placebo. MTX seems to have no added effect. Prior anti-TNF therapy seems to not influence the radiographic efficacy of IL blockers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa313","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T11:12:28Z","timestamp":1588936348000},"page":"3172-3180","source":"Crossref","is-referenced-by-count":25,"title":["Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis"],"prefix":"10.1093","volume":"59","author":[{"given":"Dongze","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou"},{"name":"Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-1680","authenticated-orcid":false,"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-2779","authenticated-orcid":false,"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-3365","authenticated-orcid":false,"given":"Yihan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Griffith","sequence":"additional","affiliation":[{"name":"Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong\u00a0and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-8852","authenticated-orcid":false,"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"2020102707114885800_keaa313-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2020102707114885800_keaa313-B2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","article-title":"Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study","volume":"42","author":"McHugh","year":"2003","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B5","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","article-title":"The effects of structural damage on functional disability in psoriatic arthritis","volume":"76","author":"Kerschbaumer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2020102707114885800_keaa313-B8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2020102707114885800_keaa313-B9","first-page":"S55","article-title":"Radiographic scoring methods in psoriatic arthritis","volume":"33","author":"Wassenberg","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2020102707114885800_keaa313-B10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"key":"2020102707114885800_keaa313-B13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2020102707114885800_keaa313-B14","first-page":"376","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kes393","article-title":"Comment on: a randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"52","author":"Sathi","year":"2013","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/rheumatology\/kes059","article-title":"Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation","volume":"51","author":"Dougados","year":"2012","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kes341","article-title":"Comment on: a randomized placebo-controlled trial of methotrexate in psoriatic arthritis: reply","volume":"52","author":"Kingsley","year":"2013","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B19","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"2020102707114885800_keaa313-B20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2012-202959","article-title":"Tumour necrosis factor alpha blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis","volume":"73","author":"Eder","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kex452","article-title":"Efficacy and safety of biologics targeting interleukin-6, -12\/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis","volume":"57","author":"Wu","year":"2018","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B22","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020102707114885800_keaa313-B23","first-page":"ii61","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64(Suppl 2","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B24","first-page":"731","article-title":"Smallest detectable difference in radiological progression","volume":"26","author":"Lassere","year":"1999","journal-title":"J Rheumatol"},{"key":"2020102707114885800_keaa313-B25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/ard.2003.018457","article-title":"Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change","volume":"64","author":"Bruynesteyn","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B26","first-page":"476","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B28","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020102707114885800_keaa313-B29","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B30","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"2020102707114885800_keaa313-B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B33","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2020102707114885800_keaa313-B34","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114885800_keaa313-B35","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B36","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114885800_keaa313-B37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2012-201580","article-title":"Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors","volume":"72","author":"Finzel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020102707114885800_keaa313-B38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020102707114885800_keaa313-B39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/rheumatology\/key417","article-title":"Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity","volume":"58","author":"Landewe","year":"2019","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B40","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology"},{"key":"2020102707114885800_keaa313-B41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"2020102707114885800_keaa313-B42","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized controlled phase 3 trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020102707114885800_keaa313-B43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3172\/34038075\/keaa313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3172\/34038075\/keaa313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T12:13:16Z","timestamp":1603800796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/11\/3172\/5881462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,5]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa313","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,5]]}}}